Atrium Medical has begun enrollment of the first patients for their CONFIRM 1, First-in-Man (FIM) drug eluting coronary stent clinical trial. Atrium's European FIM clinical trial study is evaluating Atrium's CINATRA voclosporin coated coronary stent system.
Ads by Google
ASE event provides a forum for the world's leading researchers in cardiovascular medicine to present their most-recent findings.
Many patients with heart failure -- especially younger ones and those with more severe disease -- significantly overestimate how long they are going to live.
People recovering from acute heart problems such as heart attack and heart surgery are more likely to develop habits to control heart attack risk factors when they meet regularly with cardiac disease managers.
Members of the European Parliament Heart Group meet today, 3 June, in Brussels, to discuss the link between nutrition and cardiovascular diseases and how labelling of food can help people choose products that are better for their hearts and vessels.
Most Americans don't believe they could perform cardiopulmonary resuscitation and use an automated external defibrillator to help save a life in a cardiac emergency.
OrbusNeich has received approval from the Department of Health to market the Genous Bio-engineered R stent in Taiwan.
A research study has found that a simple blood test may indicate whether post-menopausal hormone therapies present an elevated risk of a heart attack. The study, part of the Women's Health Initiative (WHI), sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, was conducted in 40 centers nationwide and included 271 cases of coronary heart disease in the first four years of the trials of estrogen alone and of estrogen plus progestin. Corresponding author Paul F.
The more than ten million Americans who've received drug-eluting stents to open their blocked coronary arteries have a bright future.
According to the American Heart Association, Minneapolis, MN, is the most 'heart friendly' city in their recently-released ranking of the most Heart Friendly Cities for Women.
Derma Sciences have used MEDIHONEY dressings to successfully treat 8 patients with deep sternal wound infections, a condition that sometimes arises after open-heart surgeries.
XIENCE V continues to deliver clinically superior benefits for patients compared to the TAXUS paclitaxel-eluting coronary stent system.
FDA has cleared for marketing a device that a doctor can use to see inside a blood vessel to assess the fat content of the plaque which builds up on the wall of the coronary arteries.
New study shows heart problems possibly leading to strock are linked with Fosamax, an osteoporosis treatment drug. Women who have used Fosamax are nearly twice as likely to develop the most common kind of chronically irregular heartbeat (atrial fibrillation) than are those who have never used it
Different races are responding to heart failure treatment drugs and this fact was remaining unexplained, but a new research now shows that the key is gene variant.
A study demonstrated that use of Abbott's XIENCE V Everolimus Eluting Coronary Stent System in patients with coronary artery disease resulted in a significant 50 percent reduction in vessel renarrowing.
Heart assist devices are surgically implanted mechanical pumps that help the heart's ventricle do its work of pumping blood to the rest of the body. Previous models were too large to be placed in the upper abdomen of some women and small-sized men. But the Thoratec HeartMate II Left Ventricular Assist System employs a first-of-a-kind design. Instead of the standard pulsatile pump that simulates the action of the heart, the device uses a continuous flow pump that constantly moves blood with a single moving part, a spinning rotor.
Researchers looked at cardiac fibrosis, which can occur in patients who have suffered an infection of the heart muscle or a heart attack. Such fibrosis causes the heart to stiffen so that it cannot adequately fill with blood and then empty itself, a condition known as diastolic dysfunction.
Beating heart CABG saved $1,684 per procedure, inclusive of the cost of the C-Port systems in the beating heart cases, compared to traditional bypass surgery.
Boston Scientific Corporation has received approval for the sale of its TAXUS Liberte paclitaxel-eluting coronary stent system in Canada. The Company reported that Health Canada's Therapeutic Products Directorate (TPD), the authority that regulates pharmaceutical drugs and medical devices, has approved its use. The Company said it plans to launch the product immediately in Canada.
Before gene therapy becomes practical for treating human diseases, researchers must master the details of safe and effective delivery. Cardiology researchers at The Children's Hospital of Philadelphia have advanced delivery techniques by creating a versatile synthetic material that can bind to a variety of gene therapy vectors and can be custom-designed for controlled local release of therapeutic genes at a disease site.
Polar's patented OwnCode technology - previously only available in Polar heart rate monitors - can now be seamlessly and cost-effectively incorporated into commercial fitness equipment, putting it within reach of thousands of manufacturers and health club owners alike.